Drugs / HB-2121
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07377565 | Apr 2026 → Jun 2027 expected | celiac disease | Nielsen Fernandez-Becker | Recruiting | No outcome recorded |
| Phase 1 | NCT07063823 | Aug 2025 → Apr 2026 | celiac disease | Nielsen Fernandez-Becker | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-2121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063823 ↗ |
| Modality | Diagnostic / imaging agent | “as a Diagnostic for Celiac Disease” NCT07377565 ↗ |
| Route | Oral | “HB-2121 taken once orally.” NCT07063823 ↗ |